Published: 2023 April 21

Antibacterial Drugs Market Trends, Growth, Demand and Market Forecast 2023-2030

SKU : PH1511
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Antibacterial Drugs Market is segmented By Action Type (Bacteriostatic, Bactericidal, By Drug Type (Beta lactams, Aminoglycosides, Tetracyclines, Macrolides, Sulfonamide, Quinolones, Others), By Route of Administration (Oral, Parenteral, others), By Drug Mechanism (Cell Wall Synthesis Inhibitors, Plasma Membrane Inhibitors, Protein Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, Others), By Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Antibacterial Drugs Market Overview

The global antibacterial drugs market reached USD 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030). 

Recently marketed antimicrobial agents and waiting for FDA approval is one of the key trends in the global antibacterial drugs market. Many new antimicrobial agents with new targets have been marketed recently, while some of them are waiting for FDA approval. Some of them include macrocyclic antibiotics, newer cephalosporins, newer glycopeptides, newer carbapenems, pleuromutilin, and and among others.

Antibacterial drugs, usually known as antibiotics, are a type of medication used for bacterial infections. Antibiotics target certain bacteria or bacterial activities, such as cell wall or protein synthesis. The precise treatment and dosage will depend on the kind and severity of the disease. Antibacterial drugs can be delivered orally, topically, and intravenously among others.

Furthermore, rising incidence of chronic diseases, rising clinical trials, increasing FDA approvals, and growing research in antibacterial drugs are the factors that are expected to drive the market growth over the forecast period.

Antibacterial Drugs Market Scope and Summary





Size Available for Years


Forecast Period


Data Availability

Value (US$) 

Segments Covered

Action Type, Drug Type, Route of Administration, Drug Mechanism, Distribution Channel and Region

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region


Largest Region

North America

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights.


For more details on this report - Request for Sample


Antibacterial Drugs Market Dynamics and Trends


The rising number of market developments is boosting the global antibacterial drugs market growth.

The growing threat posed by multidrug-resistant gram-negative organisms (MDR-GNBs) is increasing the urgency with which antibacterial medications are being developed worldwide. Pharmaceutical producers will benefit from upcoming regulatory improvements that will reduce R&D costs and incentivize novel medication identification. 

The only three established pharmaceutical companies in the antibacterial medicine space are GlaxoSmithKline, AstraZeneca, and Merck & Co. Moreover, it isn't easy to discover new antibacterial medications and uncover unique molecules that can successfully target germs. Big pharma corporations and formerly leaders are closing down their antimicrobial research centers due to the high risk of failure and costly R&D costs.

As a result, organizations such as the Food and Drug Administration (FDA) and the Infectious Diseases Society of America are launching several programs to entice corporations to return to antibacterial R&D. The recently enacted Generating Antibiotic Incentives Now (GAIN) Act is expected to promote more efficient clinical trials and lower market entry barriers. 

Furthermore, Combating Bacterial Resistance in Europe (COMBACTE) and TRANSLOCATION (molecular basis of bacterial cell wall permeability) are two projects launched by the Innovative Medicines Initiative (IMI) in Europe that demonstrate an unprecedented collaboration with industry, biotech organizations, and academia to combat antibiotic resistance. 

Stringent pricing of drugs is hampering the growth of the global antibacterial drugs market.

Drug pricing is a complicated process, involving different stakeholders, and has a large influence on cost-effectiveness. Value-based pricing is a method to determine the price of a drug at which it can be cost-effective. It is currently unclear what the influence of value-based pricing will be on the prices of new antibacterial agents, but an important factor will be the definition of value, which as well as the impact of the drug on patient health might also include other factors such as wider social impact and the health impact of the disease.

Pharmaceutical companies were reluctant to invest in the development of antibacterial agents; the revenues of the new drugs were expected to be low, because of the short use of antibacterial drugs and the high competition with many cheap generic drugs. The lack of new antibacterial agents and the growing resistance to the available drugs have limited the treatment options for infection in recent years.

Antibacterial Drugs Market Segment Analysis

The global antibacterial drugs market is segmented based on the action type, drug type, route of administration, drug mechanism,distribution channel and region.

The beta-lactams segment is expected to hold a dominant position in the market over the forecast period.

Beta-lactams segment accounted for the highest market stake accounting for approximately 40.3% of the antibacterial drugs market in 2022. The segment benefits because β-Lactams are one of the most often prescribed antibiotic classes for antibacterial treatment today. They restrict bacterial growth by blocking PBPs, which are required for cross-linking during cell wall formation.

Moreover, there are recent FDA approvals and pharmaceutical companies that have promising pipelines that are expected to drive the market growth over the forecast period. For instance, on January 30, 2023, Alkem, an India-based company, launched Zidavi, a novel combination of ceftazidime and avibactam. It is recommended by the IDSA and ICMR as a preferred treatment against OXA-48-like and Klebsiella Pneumoniae Carbapenemase (KPC)-producing Carbapenem-Resistant Enterobacteriaceae (CRE) for pyelonephritis and other CRE infections caused by KPC and OXA-48.

Source: DataM Intelligence Analysis (2023)

Antibacterial Drugs Market Geographical Penetration

North America holds a dominant position in the global antibacterial drugs market.

North America is estimated to hold around 36% of the total market share throughout the forecast period, owing to the increased antibiotic resistance, government initiatives, and increased regional FDA approvals. 

For instance, in January 2023, Juno Pharmaceuticals Canada received approval from Health Canada to import Amoxicillin powder for oral suspension Amoxicillin. This approval helps to relieve the current nationwide shortage of critical antibiotic products. The U.S. and Canada are experiencing a nationwide shortage of antibiotics. Amoxicillin oral suspension is one of the most commonly prescribed antibiotics for children to treat particular bacterial infections. 

Source: DataM Intelligence Analysis (2023)

Antibacterial Drugs Companies and Competitive Landscape

The major global players in the market include Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Novartis AG, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Melinta Therapeutics, Otsuka Pharmaceutical Co., Ltd., Insmed, Inc., Basilea Pharmaceutica, R-Pharm, Merck & Co., Inc., and Venatorx Pharmaceuticals among others.

COVID-19 Impact on Antibacterial Drugs Market

Russia Ukraine Conflict Analysis

The invasion of Ukraine by Russia has caused a severe humanitarian crisis. Civilian combatants have sustained severe wounds, leading to critical health issues. Unrestricted access to antimicrobials and Russian enmity will lead to widespread purchase and inappropriate usage. Urgent public health messages must be distributed to stop Russian tensions from worsening AntiMicrobial Resistance (AMR).

By Action Type

  • Bacteriostatic
  • Bactericidal

By Drug Type

  • Beta-lactams
  • Aminoglycosides
  • Macrolides
  • Quinolones
  • Tetracyclines 
  • Sulfonamide
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others 

By Drug Mechanism

  • Inhibition of Cell Wall Synthesis
  • Inhibition of Protein Synthesis
  • Alteration of Cell Membranes
  • Inhibition of Nucleic Acid Synthesis
  • Antimetabolite Activity

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies  
  • Online Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On September 22, 2022, GSK plc and Spero Therapeutics, Inc. entered into an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being developed by Spero, as the first oral carbapenem antibiotic to potentially treat complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.
  • On February 2, 2023, Shionogi & Co. and its European subsidiary, Shionogi B.V., announced that its innovative antibiotic, FETCROJA (cefiderocol), is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, with an increasing trend in antibiotic-resistant infections. 
  • On February 22, 2022, Sistema Group company, Binnopharm Group, acquired Dr. Reddy's Laboratories' anti-bacterial medicines underneath the Ciprolet and Levolet brands in Russia, Uzbekistan, and Belarus. 

Why Purchase the Report?

  • To visualize the global antibacterial drugs market segmentation based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of antibacterial drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global antibacterial drugs market report would provide approximately 77 tables, 76 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

For more Lifesciences and Healthcare related reports, please click here

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
What is the Projected CAGR value of the Antibacterial Drugs Market?
Antibacterial Drugs Market is expected to grow at a CAGR of 4.8% during the forecasting period 2023-2030.
Which is the fastest growing region in the Antibacterial Drugs Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
Related Reports

Antimicrobial Therapeutics Market Size, Share, Industry Trends, Outlook, Growth Opportunities and Market Forecast 2023 - 2030

Published: 2023 April 17
Starting from



United States Veterinary Pain Management Market Size, Competitive Landscape and Market Forecast - 2029

Published: 2023 March 01
Starting from



United States Veterinary Antibiotics Market Size, Competitive Landscape and Market Forecast - 2029

Published: 2022 October 19
Starting from



Anticoccidial Drugs Market Size, Share, Industry Trends, Outlook, Growth Opportunities and Market Forecast 2023 - 2030

Published: 2023 May 16
Starting from



Atherosclerosis Drugs Market Size, Competitive Landscape and Market Forecast - 2030

Published: 2023 March 30
Starting from



Europe Liver Cancer Therapeutics Market Size, Competitive Landscape and Market Forecast - 2030

Published: 2023 February 23
Starting from



Musculoskeletal Diseases Treatment Market

Published: 2023 April 17
Starting from